Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Chubb
Johnson and Johnson
Merck
US Department of Justice
Baxter

Generated: July 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,337,824

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,337,824 protect, and when does it expire?

Patent 8,337,824 protects VELTASSA and is included in one NDA.

This patent has fifty-six patent family members in twenty-three countries.

Summary for Patent: 8,337,824
Title:Linear polyol stabilized polyfluoroacrylate compositions
Abstract: The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract.
Inventor(s): Albrecht; Detlef (Saratoga, CA), Burdick; Michael (Los Altos, CA), Chang; Han-Ting (Livermore, CA), Charmot; Dominique (Campbell, CA), Chidambaram; Ramakrishnan (Pleasanton, CA), Connor; Eric (Los Gatos, CA), Halfon; Sherin (Palo Alto, CA), Huang; I-Zu (Mountain View, CA), Liu; Mingjun (Campbell, CA), Mills; Jonathan (San Jose, CA), Struver; Werner (Leverkusen, DE)
Assignee: Relypsa, Inc. (Santa Clara, CA)
Application Number:12/545,810
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,337,824
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,337,824
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Use;

Drugs Protected by US Patent 8,337,824

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERKALEMIA ➤ Sign Up
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-002 Oct 21, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERKALEMIA ➤ Sign Up
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERKALEMIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
QuintilesIMS
Fish and Richardson
Covington
AstraZeneca
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.